

## XOLAIR (OMALIZUMAB) INJECTION ORDERS P: 877.365.5566 | F: 855.889.2946

| <b>PATIENT INFORMATION:</b> Fax completed form, insurance information, and clinical documentation to 855.889.294  |  |  |
|---|--|--|
| Patient Name: Phone: DOB: Phone:  |  |  |
| Patient Status:  New to Therapy  Continuing Therapy  Next Treatment Date:   |  |  |
| MEDICAL INFORMATION   |  |  |
| Diagnosis:  |  |  |
| Moderate Persistent Asthma, uncomplicated (ICD-10: J45.40)  |  |  |
| Severe Persistent Asthma, uncomplicated (ICD-10: J45.50)  |  |  |
| 🗌 Allergic Urticaria (ICD-10: L50.0)  |  |  |
| 🗌 Idiopathic Urticaria (ICD-10: L50.1)  |  |  |
| 🗌 Urticaria, unspecified (L50.9)  |  |  |
| Polyp of the Nasal Cavity (ICD-10: J33.0)   |  |  |
| Polypoid Sinus Degeneration (ICD-10: J33.1)   |  |  |
| □ Nasal Polyp, unspecified (ICD-10: J33.9)  |  |  |
| □ Other: (ICD-10:)  |  |  |
|   |  |  |
|   |  |  |
| Patient Weight: lbs. (required) Allergies:  |  |  |
|   |  |  |
| THERAPY ORDER   |  |  |
| Xolair Dose:  |  |  |
| □ 150mg □ 225mg □ 300mg □ 375mg □ 450mg □ 525mg □ 600mg   |  |  |
|   |  |  |
| <b>Frequency</b> : Subcutaneously Every: 2 weeks x 1 year OR 4 weeks x 1 year   |  |  |
| *Note: Patient must have an EpiPen in their possession on their appointment date.   |  |  |
| Note. Fatient must have an Epir en in their possession on their appointment date.   |  |  |
|   |  |  |
| Other orders:   |  |  |
|   |  |  |
| Lab Orders: Lab Frequency:  |  |  |
| Required labs to be drawn by:   |  |  |
|   |  |  |
|   |  |  |
| PROVIDER INFORMATION  |  |  |
| By signing this form and utilizing our services, you are authorizing Paragon Healthcare, Inc. and its employees to serve as your prior authorization and specialty pharmacy designate agent in dealing with medical and prescription insurance companies, and to select the preferred site of care for the patient. |  |  |
| Provider Name:  |  |  |
| Provider NPI: Phone: Fax: Contact Person:   |  |  |
| □ Opt out of Paragon selecting site of care (if checked, please list site of care):   |  |  |
| PREFERRED LOCATION  |  |  |
|   |  |  |
| City: State: View our locations here:   |  |  |
|   |  |  |
| PARAGONHEALTHCARE.COM   |  |  |

IMPORTANT NOTICE: This fax is intended to be delivered only to the named address and contains material that is confidential, privileged property, or exempt from disclosure under applicable law. If you are not the named addressee, you should not disseminate, distribute, or copy this fax. Please notify the sender immediately and destroy all copies if you have received this document in error.



## **PATIENT INFORMATION:**

| Patient Name: DOE  | 3:                 |
|--|--------------------|
| <b>REQUIRED DOCUMENTATION FOR REFERRAL PROCESSING &amp; INSURAN</b>  | CE APPROVAL        |
| Include <u>signed</u> and <u>completed</u> order (MD/prescriber to complete page 1   | )                  |
| $\Box$ Include patient demographic information and insurance information   |                    |
| Include patient's medication list  |                    |
| □ Supporting clinical notes to include any past tried and/or failed therapie<br>benefits, or contraindications to conventional therapy   | es, intolerance,   |
| <ul> <li>Please indicate any tried and failed therapies (if applicable):</li> <li>Corticosteroids</li> </ul>   |                    |
| Long acting beta 2 agonist   |                    |
| Long acting muscarinic antagonist  |                    |
| Antihistamines: Other:   |                    |
| <ul> <li>Asthma - Does the patient have a history of 2 exacerbations requiring oral/systemic corticosteroids, hospitalization or an emergency room 12-month period?</li> </ul>   |                    |
| ☐ Asthma - Does the patient have an ACQ score consistently greater th score consistently less than 120?  | an 1.5 or ACT      |
| ☐ Nasal polyps - Does the patient have significant rhinosinusitis symptom nasal obstruction, rhinorrhea, or loss of smell? ☐ Yes ☐ No  | oms such as        |
| □ Include labs and/or test results to support diagnosis  |                    |
| <ul> <li>Asthma &amp; Polyps - Does patient have a baseline IgE level of ≥ 30 IU/r</li> <li>Yes □ No (required - attach results)</li> </ul>  | mcL?               |
| Asthma - Does the patient have an allergy to a perennial aeroallerger  | n? 🗌 Yes 🗌 No      |
| Pulmonary Function Tests or FEV1 score (if applicable):  |                    |
| □ Is the patient or caregiver <u>able</u> to administer Xolair for self-administration.<br>□ Yes □ No If no, please state reason:  |                    |
| $\Box$ Is the patient a candidate for home therapy? ( <b>UHC only</b> ) $\Box$ Yes $\Box$ No   |                    |
| Other medical necessity:   |                    |
| Paragon Healthcare will complete insurance verification and submit all required document<br>al to the patient's insurance company for eligibility. Our team will notify you if any addition<br>required. We will review financial responsibility with the patient and refer him/her to any a | nal information is |

assistance as needed. Thank you for the referral. Please fax all information to (855) 889-2946 or call (877) 365-5566 for assistance